Avricore Health Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Vancouver, british columbia, april 30, 2024 (globe newswire) -- avricore health inc. (tsxv: avcr) (the "company" or “avcr”) is pleased to announce its audited results for 2023.

Vancouver, british columbia, april 04, 2024 (globe newswire) -- avricore health inc.  (tsxv: avcr, otc: avcrf) (“avricore health” or the “company”) is pleased to announce further expansion of healthtab™ with rexall pharmacy group ulc (“rexall”). the companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful deployment of this powerful point-of-care testing platform.

Vancouver, british columbia, nov. 30, 2023 (globe newswire) -- avricore health inc. (tsxv: avcr) (the "company" or “avcr”) reports on its third quarter results which demonstrate significant growth in pharmacy locations offering healthtab driving strong revenue growth and operational cashflow positivity.

Vancouver, british columbia, sept. 15, 2023 (globe newswire) -- avricore health inc.  (tsxv: avcr, otc: avcrf) (“avricore health” or the “company”) is expanding its innovative point-of-care chronic and infectious disease screening and health-data management platform, healthtab™, further into the canadian pharmacy ecosystem with one of canada's largest pharmacy retailers, rexall pharmacy group ulc (“rexall”).

Vancouver, british columbia, aug. 30, 2023 (globe newswire) -- avricore health inc. (tsxv: avcr) (the "company" or “avcr”) continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. now, as the company looks back at the first half of the year, it continues with confidence on its strategy to bring healthtab™, its turnkey solution for point of care testing and data management, to more pharmacies across canada and the world.

Avricore Health (TSX-V:AVCR, OTC:AVCRF) said it grew the number of pharmacy locations offering HealthTab during the third quarter of 2023, which led to an increase in revenue. In the three months ending September 30, 2023, revenue increased by 27% YoY to $953,454, with a gross profit rise of 21% to $261,778.

Avricore Health (TSX-V:AVCR, OTC:AVCRF) said it in the first half of 2023 it continues to surpass financial targets, strike partnerships, and develop new markets as it brings its turkey solution for point-of-care testing HealthTab to additional pharmacies across Canada and internationally. The company noted that its first-half earnings were up 437% at $1,177,290 compared to the same period last year with more HealthTab systems deployed and tets sold.

Avricore Health (TSX-V:AVCR, OTC:AVCRF) Inc has announced the signing of a reseller agreement between HealthTab Inc, the company's point-of-care testing solution, and Abbott Rapid Dx UK & Ireland.  The pharmacy service innovator said the agreement provides a foundation for HealthTab to purchase and distribute the Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.

Avricore Health (TSX-V:AVCR, OTC:AVCRF) announced that it has partnered with Ascensia Diabetes Care to integrate its blood glucose monitoring systems with Avricore's pharmacy-based point-of-care testing platform HealthTab. Avricore said the objective of the partnership is to support patients and pharmacists in Canada to better manage diabetes by linking daily blood glucose testing results and pattern history data collected via Ascensia's CONTOUR NEXT GEN or CONTOUR NEXT ONE meters to the patient's HealthTab account.

Avricore Health (TSX-V:AVCR, OTC:AVCRF) Inc, which is focused on delivering point-of-care testing and data solutions for pharmacies through its turnkey solution HealthTab, revealed that it has expanded its HealthTab network to the point where it has crossed 532 locations. The Vancouver-based pharmacy service innovator said that in 100 of these locations it will be deploying Abbott's ID Now, either in combination with Afinion 2 or as a standalone for virus detection and to assess the demand for infectious disease screening in community pharmacies.

Avricore Health (TSX-V:AVCR, OTC:AVCRF) Inc was recognized as one of the 2023 Venture 50, the TSX Venture Exchange's list of top-performing companies. “To make the Venture 50 feels great and the whole team is excited to keep delivering on our promise to build the world's largest rapid-testing network in pharmacy,” said Hector Bremner, CEO of Avricore Health (TSX-V:AVCR, OTC:AVCRF), in a statement.

Avricore Health (TSX-V:AVCR, OTC:AVCRF) Inc said it has successfully entered the second year of a multi-year growth plan to bring its flagship HealthTab network, a turnkey point-of-care data management and testing solution, to more pharmacies. In a corporate update, the Vancouver, British Columbia-based pharmacy service innovator provided insights into its achievements last year and spelt out its key objectives for 2023.

Imagine being able to access a wealth of data about your health by simply visiting your local pharmacy.  If you think this concept sounds familiar, you're right.

Avricore Health (TSX-V:AVCR, OTC:AVCRF) Inc posted third quarter results that saw its revenue jump 662% year-over-year as the company successfully scaled its flagship HealthTab network, a turnkey point-of-care testing solution.    For the period that ended September 30, 2022, the Vancouver, British Columbia-based pharmacy service innovator reported revenue of $572,228, compared to $75,104 in the third quarter of 2021.

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) announces the availability of a broadcast titled, “Real-World Data, Point-of-Care Testing Reshaping Healthcare, Detecting Diseases Sooner.”